Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co Scaled Net Operating Assets Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
Scaled Net Operating Assets
0.51
0.53
0.62
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Scaled Net Operating Assets
0.51
0.00
0.00
0.62
0.68
HKSE:02575 vs ZTS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.68 mean?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a Scaled Net Operating Assets of 0.68 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets too high?
Xuanzhu Biopharmaceutical Co's current Scaled Net Operating Assets is 0.68. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets compare to ZTS?
Xuanzhu Biopharmaceutical Co's Scaled Net Operating Assets of 0.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current Scaled Net Operating Assets is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current Scaled Net Operating Assets of 0.68. The current Scaled Net Operating Assets is 0.68. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current Scaled Net Operating Assets is 0.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for HKSE:02575
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02575 has been successfully added to your 
